Concept Medical Enrolls First Patient in MAGICAL BTK Study for Below-the-Knee PAD Treatment

Concept Medical Enrolls First Patient in MAGICAL BTK Study for Below-the-Knee PAD Treatment

January 17, 2025 Catherine Williams - Chief Editor Health

Concept Medical Enrolls First Patient in Landmark MAGICAL BTK Study for Below-the-Knee Peripheral Artery Disease

TAMPA, Fla., Jan. 17, 2025 — Concept Medical Inc., a global leader in innovative drug delivery technologies, has achieved a significant milestone with the successful enrollment of the first patient in its pivotal MAGICAL BTK study. This randomized controlled trial evaluates the safety and efficacy of the MagicTouch PTA sirolimus-coated balloon compared to standard percutaneous transluminal angioplasty (PTA) for treating below-the-knee peripheral artery disease (PAD). The study, conducted under an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA), marks a critical step forward in advancing treatment options for patients suffering from this debilitating condition.

The first patient was enrolled by Dr. Prakash Krishnan and his team at the Icahn School of Medicine at Mount Sinai, signaling the start of Concept Medical’s U.S.-based peripheral clinical trial program. This achievement comes on the heels of the FDA’s recent IDE approval for MagicTouch PTA, further solidifying the company’s commitment to improving patient outcomes through cutting-edge vascular interventions.

“The enrollment of the first patient in the MAGICAL BTK study represents a pivotal step toward enhancing the standard of care for below-the-knee disease in patients with PAD,” said Dr. Krishnan. “The sirolimus-coated balloon technology has the potential to significantly improve limb salvage and patient quality of life. I am proud to be part of this historic study and look forward to the meaningful clinical evidence it will generate.”

The MAGICAL BTK study is designed to assess the safety and efficacy of the MagicTouch PTA sirolimus-coated balloon, with primary patency at 12 months as the primary endpoint. This global, multicenter trial is led by Prof. Sahil Parikh (Chair) and includes a distinguished panel of principal investigators, including Dr. Eric Secemsky (Beth Israel Deaconess Hospital and Harvard Medical School), Prof. Brian DeRubertis (NY Presbyterian Weill Cornell Medical Center and Cornell University Medical College), Prof. Edward Choke (Northern Heart Hospital), and Prof. Osamu Iida (Osaka Keisatsu Hospital).

“The initiation of the MAGICAL BTK study heralds a new era in treating patients with chronic limb-threatening ischemia, offering hope to millions at risk of losing their limbs due to insufficient arterial circulation in their legs,” said Prof. Parikh.

MagicTouch PTA’s sirolimus-coated balloon technology has already transformed the management of coronary and peripheral artery disease, with positive outcomes demonstrated in large-scale studies across Asia and Europe. The MAGICAL BTK study now brings this innovative approach to U.S. patients, while also expanding enrollment in Asia to provide a more comprehensive understanding of the therapy’s benefits across diverse populations.

“At Concept Medical, our unwavering commitment to innovation and patient care drives us to push the boundaries of what’s possible in vascular interventions,” said Dr. Manish Doshi, founder and CEO. “The launch of MAGICAL BTK further validates our dedication to delivering evidence-based, next-generation solutions to physicians and patients worldwide. Our goal is to redefine current standards, ensuring better outcomes and improved quality of life for those affected by PAD.”

With the MAGICAL BTK study underway and the MAGICAL SFA IDE study for superficial femoral artery (SFA) treatment set to begin, Concept Medical is poised to revolutionize endovascular care. The company’s proprietary drug delivery platforms have already elevated the management of coronary artery disease and are now expanding into peripheral interventions, reinforcing its leadership in advancing patient-centric solutions.

About Concept Medical Inc.

Headquartered in Tampa, Florida, Concept Medical Inc. is a global innovator dedicated to improving patient care through cutting-edge research and development in drug delivery technologies. Its patented platforms are designed to deliver pharmaceutical agents to vascular luminal surfaces with unparalleled precision. Concept Medical is the developer of the MagicTouch family of sirolimus-coated balloons (SCBs), the world’s first and most widely used SCB technology, renowned for its versatility and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have been used to treat over one million patients worldwide, setting a new standard in vascular therapy.

For more information, visit www.conceptmedical.com.

Photo: https://mma.prnewswire.com/media/2600214/Magical_BTK_First_Patient_Enrolled.jpg
Logo: https://mma.prnewswire.com/media/1926812/5120910/Concept_Medical_Logo.jpg

Conclusion

The enrollment of the first patient in the MAGICAL BTK ​study marks a transformative moment ‍in the treatment‌ of below-the-knee peripheral artery disease (PAD). By evaluating the safety and ⁤efficacy of the MagicTouch PTA sirolimus-coated balloon, this​ landmark study ‍has the ‍potential to redefine the standard of care for patients suffering from chronic limb-threatening ischemia. With a distinguished team‍ of global investigators and the backing ​of the FDA’s Investigational Device Exemption, Concept Medical is poised⁣ to deliver groundbreaking insights that could⁤ substantially‍ improve limb salvage rates​ and enhance the quality of life for millions ‌of patients worldwide.

As the study progresses, the collaboration between leading medical institutions and the innovative sirolimus-coated balloon⁣ technology ⁤underscores a shared commitment to advancing vascular ⁢interventions. The MAGICAL⁣ BTK study not only represents a​ critical step forward in addressing unmet ⁤clinical⁤ needs but also reinforces Concept Medical’s position‍ as a pioneer⁤ in drug ⁢delivery technologies. With‍ the promise of meaningful clinical evidence ⁣on the horizon, this trial offers hope to patients at risk of limb⁣ loss and sets the stage for a new era ‌in ‍the management of below-the-knee ⁣PAD.The future of vascular ‍care is brighter than ever, and the MAGICAL BTK⁤ study is‌ at the forefront of ​this‌ evolution.
The prosperous enrollment of the first patient in the MAGICAL BTK study marks a transformative moment in the treatment of below-the-knee peripheral artery disease (PAD). This landmark trial,led by a distinguished team of global experts,underscores Concept Medical’s commitment to advancing innovative solutions for patients suffering from chronic limb-threatening ischemia. By evaluating the safety and efficacy of the MagicTouch PTA sirolimus-coated balloon, the study has the potential to redefine the standard of care, offering hope to millions at risk of limb loss and significantly improving thier quality of life.

As Concept Medical continues to expand its clinical trial programs, including the upcoming MAGICAL SFA study, the company is solidifying its position as a global leader in drug delivery technologies. with a proven track record in coronary and peripheral artery disease management, Concept Medical’s dedication to evidence-based innovation and patient-centric care is driving meaningful progress in vascular interventions. The MAGICAL BTK study not only represents a critical step forward in addressing unmet clinical needs but also highlights the company’s unwavering mission to deliver next-generation solutions that empower physicians and transform patient outcomes worldwide.

As the trial progresses, the medical community eagerly anticipates the insights it will yield, paving the way for a new era in endovascular care. Concept Medical’s pioneering efforts are a testament to the power of innovation, collaboration, and a steadfast focus on improving lives—one breakthrough at a time.